Complicaciones no infecciosas del paciente con infección por el virus de la inmunodeficiencia humana

  1. Soler Gómez, A. 1
  2. Soto Cárdenas, M.J. 1
  3. Corrales Cuevas, M. 1
  4. Trillo Marín, A. 1
  1. 1 Servicio de Medicina Interna General, Enfermedades Infecciosas y Cuidados Paliativos, Hospital Universitario Puerta del Mar, Cádiz, España
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2022

Titel der Ausgabe: Enfermedades infecciosas (IX)

Serie: 13

Nummer: 57

Seiten: 3345-3352

Art: Artikel

DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Zusammenfassung

El aumento de la esperanza de vida desde la introducción del tratamiento antirretroviral (TAR), junto con el envejecimiento de la población con infección por el VIH, ha motivado que en los últimos años haya crecido el interés por las complicaciones no infecciosas descritas en estos pacientes, en los que se ha detectado un incremento de la incidencia de tumores no asociados a SIDA, complicaciones hepáticas y cardiovasculares, entre otros eventos, y que actualmente se asocian con una importante morbimortalidad. En esta actualización, abordaremos los aspectos más relevantes de las principales complicaciones no infecciosas que presentan los pacientes con infección por el VIH en la actualidad y los aspectos clave a valorar durante el seguimiento.

Bibliographische Referenzen

  • Park LS, Hernández Ramírez RU, Silverberg MJ, Crothers K DR. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016;30:273-91.
  • García Abellán J, del Río L, García JA, Padilla S, Vivancos MJ, del Romero J. Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte CoRIS. Enferm Infecc Microbiol Clin. 2019;37:502-8.
  • Santos J, Valencia E, coordinadores, GeSIDA. Guía de práctica clínica sobre los tumores no definitorios de sida e infección por el VIH. 2019;1-71.
  • Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA. Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States. JAMA Intern Med. 2017;177:1613-21.
  • Wang YH, Shen XD. Human immunodeficiency virus infection and mortality risk among lung cancer patients: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0361.
  • Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti DM S-MS. Reduced cancer survival among adults with HIV and an AIDS-defining illnesses despite no difference in cancer stage at diagnosis. J Acquir Immune Defic Syndr. 2018;79:421-9.
  • Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4:e67-73.
  • Merchante N, Merino E, López Aldeguer J, Jover F, Delgado Fernández M, Galindo MJ. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis. 2013;56:143-50.
  • Merchante N, Rodríguez Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ. Hepatocellular carcinoma after sustained viro- logical response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS. 2018;32:1423-30.
  • Piketty C, Selinger Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS. 2008;22:1203-11.
  • Viciana P, Milanés Guisado Y, Fontillón M, Domínguez Castaño A, Sotomayor C, Espinosa N. High-risk human papilloma virus testing improves diagnostic performance to predict moderate to high grade anal intraepithelial neoplasia in human immunodefi- ciency virus infected men who have sex with men in low to absent cytological abnormalities. Clin Infect Dis. 2019;69:2185-92.
  • Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López Cortés LF. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056-63.
  • Hernando V, Pérez Cachafeiro S, Lewden C, González J, Segura F, Oteo JA. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection. J Hepatol. 2012;57:743-51.
  • Corma Gómez A, Morano L, Téllez F, Rivero Juárez A, Real LM, Alados JC. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS. 2019;33:1167-74.
  • Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-6.
  • Shah AS, Stelzle D, Lee KK, Beck E, Alam S, Clifford S. Global burden of atherosclerotic cardiovascular disease in people living with the human immunodeficiency virus: A systematic review and meta-analysis. Circulation. 2018;138:1100-12.
  • Kaplan Lewis E, Aberg JA, Lee M. Atherosclerotic cardiovascular disease and anti-retroviral therapy. Curr HIV/AIDS Rep. 2016;13:297-308.
  • Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol. 2015;4:56-77.
  • Thompson Paul AM, Lichtenstein KA, Armon C, FJP, Skarbinski J, Chmiel JS. Cardiovascular disease risk prediction in the hiv outpatient study. Clin Infect Dis. 2017;63:1508-16.
  • Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association. Circulation. 2019;140: e98-124.
  • Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014;43:685-96.
  • Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61.
  • Mallipattu SK, Salem F, Wyatt CM. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 2014;86:259-65.
  • Knobel H, Domingo P, Suárez Lozano I, Gutiérrez F, Estrada V, Palacios R. Prevalencia de enfermedad cardiovascular, renal y ósea, y sus principales factores de riesgo en personas infectadas por el VIH que reciben tratamiento antirretroviral en España. Enferm Infecc Microbiol Clin. 2019;37:373-9
  • Kooij KW, Vogt L, Wit FWNM, Van Der Valk M, Van Zoest RA, Goorhuis A. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis. 2017;216:622-31.
  • Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis. Medicine (Baltimore). 2016;95: e5146
  • Casado JL, Bañon S, Andrés R, Pérez Elías MJ, Moreno A, Moreno S. Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients. Osteoporos Int. 2014;25: 1071-9.
  • Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL Cross-talk. J Biol Chem. 2003;278: 48251-8.
  • Arboleya L, Casado E, Casta S, Fiter J, Gifre L, Vaquero CG. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. Reumatol Clínica. 2018;15:188-210.
  • Estrada V, Domingo RP, Gutiérrez F, Galindo MJ, Knobel H. Documento de consenso sobre la osteoporosis en la infección por el VIH. 2016;49.
  • Jong E, Oudhoff LA, Epskamp C, Wagener MN, Van Duijn M, Fischer S. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS. 2010;24:1387-405.
  • Ellis RJ, Calero P, Stockin MD. HIV infection and the central nervous system: A primer. Neuropsychol Rev. 2009;19:144-51.
  • Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-51.
  • Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K. Neurocognitive change in the era of HIV combination antiretroviral therapy: The longitudinal CHARTER study. Clin Infect Dis. 2015;60: 473-80.
  • Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA CM. Updated research nosology for HIV-associated neurocognitive di- sorders. Neurology. 2007;69:1789-99.
Fuente de los datos: Dialnet